Clinical Trial: Biofeedback for Fecal Incontinence
This study is currently recruiting patients.
Verified by National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) July 2005
| Sponsored by: | National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) | | Information provided by: | National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) | | ClinicalTrials.gov Identifier: | NCT00124904 | |
Purpose
Fecal
incontinence affects 2% of adults in the U.S.
Biofeedback has been recommended for the treatment of
fecal incontinence because uncontrolled studies over the past 25 years suggest that these treatments are as effective as medical or surgical management and involve no risk. However,
placebo-controlled trials are still lacking. The aims of this study are (1) to compare
biofeedback to alternative therapies for which patients have a similar expectation of benefit; (2) to identify which patients are most likely to benefit; and (3) to assess the impact of treatment on quality of life.
| Condition | Intervention |
Fecal Incontinence
| Behavior: Biofeedback Behavior: Kegel exercises
|
MedlinePlus related topics: Anal and Rectal Diseases
Study Type: Interventional
Study Design: Treatment, Randomized, Single Blind, Active Control, Parallel Assignment, Efficacy Study
Official Title: Biofeedback for Fecal Incontinence and Constipation
Further Study Details:
Primary Outcomes: Proportion of subjects reporting adequate relief per treatment group
Secondary Outcomes: Demonstrate association of improvement in
quality of life with treatment outcome; Identify predictors of successful treatment outcome
Expected Total Enrollment: 165
Study start: September 1999; Expected completion: June 2007
Last follow-up: December 2006; Data entry closure: December 2006
Study I is a long-term, prospective,
single-blind study comparing
biofeedback for
fecal incontinence to a
standard therapy (Kegel exercises) that is associated with a similar expectation of improvement (i.e., comparable
placebo effect). Prior to randomization, patients will receive medical
therapy (antidiarrheal medications as appropriate) and education for 4 weeks, and only patients who remain incontinent will be randomized.
Anal canal squeeze pressures and
rectal sensory thresholds will be tested before and after treatment. Patients will keep a diary throughout baseline and treatment, and they will be re-assessed at 3, 6, and 12 months. Treatment will consist of 6 clinic visits at 2-week intervals. The primary outcome is the patient''''s
response to the question, "Have you had satisfactory relief of
fecal incontinence (yes/no)?" This question is asked at 3 months following the end of treatment and at each
follow-up visit. We will develop a detailed treatment manual for
fecal incontinence which would permit other investigators to
replicate our study.
Eligibility
Ages Eligible for Study: 16 Years and above, Genders Eligible for Study: Both
Criteria
Inclusion Criteria: Males or females age 16 or above who have an average of one or more episode of fecal incontinence per week
Exclusion Criteria: Previous biofeedback treatment
Location and Contact Information
Please refer to this study by ClinicalTrials.gov identifier NCT00124904
Steve Heymen, MS 919-966-2515 steve_heymen@med.unc.edu
North Carolina University of North Carolina Department of Medicine, Chapel Hill, North Carolina, 27599, United States; Recruiting
Tony G Waldrop, PhD 919-966-3411 tony_waldrop@unc.edu
William E Whitehead, PhD, Principal Investigator
Steve Heymen, MS, Sub-Investigator
Yolanda Scarlett, MD, Sub-Investigator
Yehuda Ringel, MD, Sub-Investigator
Douglas A Drossman, MD, Sub-Investigator
Study chairs or principal investigators
William E Whitehead, PhD, Principal Investigator, University of North Carolina
More Information
Center website
Publications
Palsson OS, Heymen S, Whitehead WE. Biofeedback treatment for functional anorectal disorders: a comprehensive efficacy review. Appl Psychophysiol Biofeedback. 2004 Sep;29(3):153-74. Review.
Heymen S. Psychological and cognitive variables affecting treatment outcomes for urinary and fecal incontinence. Gastroenterology. 2004 Jan;126(1 Suppl 1):S146-51. Review.
Heymen S, Jones KR, Ringel Y, Scarlett Y, Whitehead WE. Biofeedback treatment of fecal incontinence: a critical review. Dis Colon Rectum. 2001 May;44(5):728-36.
Study ID Numbers: RO1 DK57048a
Last Updated: July 29, 2005
Record first received: July 27, 2005
ClinicalTrials.gov Identifier: NCT00124904
Health Authority: United States: Federal Government
ClinicalTrials.gov processed this record on 2005-08-02
Source: ClinicalTrials.gov
Cache Date: August 3, 2005